Advertisement

U.S. markets open in 46 minutes

S&P Futures
4,156.25
-19.50(-0.47%)
Dow Futures
34,078.00
-128.00(-0.37%)
Nasdaq Futures
12,727.75
-49.00(-0.38%)
Russell 2000 Futures
1,965.40
-13.90(-0.70%)
Crude Oil
77.97
+0.83(+1.08%)
Gold
1,887.10
+2.30(+0.12%)

Advertisement

Pfizer Inc. (PFE)

NYSE - NYSE Delayed Price. Currency in USD

Visitors trend2W10W9M

43.59

-0.17

(-0.39%)

At close: 04:03PM EST

43.57

-0.02

(-0.05%)

Pre-Market:

08:43AM EST

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

MACD

View all chart patterns

Performance Outlook

Previous Close	43.76
Open	43.82
Bid	43.50 x 4000
Ask	43.50 x 1100
Day's Range	43.25 - 43.90
52 Week Range	41.45 - 56.32
Volume	22,923,869
Avg. Volume	22,138,721

Market Cap	244.684B
Beta (5Y Monthly)	0.58
PE Ratio (TTM)	7.97
EPS (TTM)	5.47
Earnings Date	May 01, 2023 - May 05, 2023
Forward Dividend & Yield	1.64 (3.75%)
Ex-Dividend Date	Jan 26, 2023
1y Target Est	52.81

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Near Fair Value

0% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for PFE

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Pfizer, Inc.
Analyst Report: Pfizer Inc.Pfizer is a leading global developer and manufacturer of pharmaceuticals and biotech drugs. Its products include oncology and immunology drugs, treatments for rare diseases, and vaccines.
Rating
Fair Value
Economic Moat
2 days agoArgus Research

All

Zacks
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- Here is What to Know Beyond Why CrowdStrike (CRWD) is a Trending Stock
  Zacks
- Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
  Zacks
TheStreet.com
Can Pfizer's Charts and Fundamentals Get on the Same Page?
The pharmaceutical giant gained an analyst's buy recommendation but its technical signals are lackluster at best.
Motley Fool
This Healthcare Giant Expects Revenue to Crash More Than 30% This Year
Last year was a stellar one for Pfizer (NYSE: PFE). In January, Pfizer announced not only its latest earnings results but also a forecast for 2023, which tells investors what they already knew was inevitable: a sharp decline in sales is coming. A decline in revenue isn't a shock given that concerns surrounding COVID appear to be fading, but the reason for the soft numbers isn't entirely due to demand.